Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment
Frontiers in Hematology · 16.11.2026 · 5
DOI: 10.3389/frhem.2026.2007169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Hematology, online erschienen am 16.11.2026. Verfasst von Marcela Barrios und 4 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Direct detection of circulating chimeric antigen receptor T (CAR-T) cells by flow cytometry provides information complementary to B-cell aplasia during immune monitoring after anti-CD19 CAR-T therapy. We describe the implementation and operational assessment of a multiparametric flow cytometry workflow for anti-CD19 CAR-T cell monitoring within an academic point-of-care cellular therapy program in Uruguay.
Methods
The assay was established for CAR-T product control and post-infusion monitoring. Technical implementation used an 8-color production panel and a locally adapted clinical monitoring panel on a 13-color DxFLEX cytometer. CAR detection used a biotinylated CD19 CAR Detection Reagent followed by PE-conjugated anti-biotin. Reagent titration, gating strategy, and an analytical sensitivity framework based on previously published criteria were assessed. B-cell aplasia was evaluated in a separate 10-color tube.
Results
The workflow was integrated into routine laboratory practice and applied during the initial clinical phase of the program. A working condition of 2 µL of CD19 CAR Detection Reagent and 2 µL of PE-conjugated anti-biotin were selected according to signal-to-noise performance and reagent use. For low-frequency interpretation, the analytical framework used a limit of blank of 8 events, a limit of detection of 13 events, and a lower limit of quantification of 22 events, adopted from published criteria rather than derived from a complete local recalculation. The method enabled direct CAR-T detection, assessment of B-cell aplasia, and characterization of CD4/CD8 distribution within the CAR-positive population.
Conclusion
Flow cytometry provided an integrated, locally available immune-monitoring strategy for an academic anti-CD19 CAR-T program, combining direct CAR-T detection with assessment of the B-cell compartment and T-cell phenotype. This operational experience may inform cellular therapy programs working under similar resource and implementation conditions.
Zitieren
APA
Barrios, M., Pereira, M. I., Ceriani, V., D’Andrea, L., & Castillo, L. (2026). Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment. Frontiers in Hematology, 5. https://doi.org/10.3389/frhem.2026.2007169
Vancouver
Barrios M, Pereira MI, Ceriani V, D’Andrea L, Castillo L. Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment. Frontiers in Hematology. 2026;5. doi:10.3389/frhem.2026.2007169
BibTeX
@article{Barrios2026,
author = {Barrios, Marcela and Pereira, Maria Inés and Ceriani, Vittoria and D’Andrea, Lucía and Castillo, Luis},
title = {Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment},
journal = {Frontiers in Hematology},
year = {2026},
volume = {5},
doi = {10.3389/frhem.2026.2007169}
}
EUVIMED